Skip to main content

Table 4 Cost of monthly therapy

From: Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

Product

DDD, mg

Cost of DDD,

Cost of monthly therapy,

Relative difference in the

BGN (EUR)

BGN (EUR)

cost versus PIO or PIO + MET, %

PIO

30

1.56156 (0.79841)

46.84 (23.95)

-

SIT

100

2.64929 (1.35456)

79.48 (40.64)

+70

VIL

100

2.73429 (1.39802)

82.03 (41.94)

+75

PIO + МET 15/850 mg

30/2000

1.68522 (0.86164)

50.56 (25.85)

-

PIO + МET 15/1000 mg

30/2000

1.68522 (0.86164)

50.56 (25.85)

-

SIT + MET 50/850 mg

100/2000

3.18204 (1.62695)

95.46 (48.81)

+89

SIT + MET 50/1000 mg

100/2000

3.20408 (1.63822)

96.12 (49.15)

+90

VIL + МET 50/850 mg

100/2000

3.24533 (1.65931)

97.36 (49.78)

+93

VIL + MET 50/1000 mg

100/2000

3.08333 (1.57407)

92.50 (47.29)

+83